Pharmacokinetics and Safety of Single‐Dose Apraglutide in Individuals with Normal and Impaired Hepatic Function: A Phase 1, Open‐Label Trial

Ähnliche Einträge

• A Phase 1, Open‐Label, Single‐Dose Study of the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib, an FGFR Inhibitor
  von: Wei Zhu, et al.
  Veröffentlicht: (2026)
• Effect of Renal Impairment on the Pharmacokinetics and Safety of Doxecitine and Doxribtimine: A Single‐Dose Phase 1 Study
  von: Aravind Mittur, et al.
  Veröffentlicht: (2026)
• Safety and Pharmacokinetics of Single‐Dose Mirikizumab in Chinese Healthy Participants: Results From a Phase 1 Study
  von: Junyu Xu, et al.
  Veröffentlicht: (2024)
• Safety, Tolerability, and Pharmacokinetics of Single‐ and Multiple‐Ascending Doses of Sunobinop in Healthy Participants
  von: Alessandra Cipriano, et al.
  Veröffentlicht: (2024)
• Correction to “Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsenin Hepatitis B Virus–Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses”
  Veröffentlicht: (2025)